Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Was suicide attempted?

Did loved one commit suicide?

What condition was this medication prescribed to treat?

What additional medications were you taking at the time?

If patient did commit suicide, what was the method of suicide?

If patient did attempt or commit suicide, did patient ever attempt suicide previously?

Please describe any psychiatric conditions diagnosed before starting Neurontin:

Did Neurontin help the condition that it was prescribed for?

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Neutrontin Side Effects Lawsuits | Side Effects: Suicidal Behavior, Suicide, Suicidal Ideation

Neutrontin Side Effects May Lead To Suicide Lawsuits

Neutrontin | Lawsuits, Lawyers | Side Effects: Suicidal Behavior, Suicide, Suicidal Ideation

News Article On Neurontin

Neurontin Suicide Link Neurontin (Generic: Gabapentin) may be linked to suicide and suicide attempts. Neurontin is prescribed for epilepsy but has been prescribed for numerous off label uses. Neurontin was approved for sale in the mid-1990s as a treatment for epileptic seizures. However, it is believed that about 80% of all Neurontin prescriptions are written for conditions other than what the drug was approved to treat.

Neurontin Off Label Prescriptions

It is believed that Parke-Davis, which was acquired by Pfizer in 2000, had a systematic strategy to market and promote Neurontin for untested uses, such as chronic pain, bipolar disorder and migraines. It is not illegal for a doctor to prescribe a drug for conditions outside of those it was approved for, however it is illegal for a drug company to market a medication for off label uses. In July 2003, Dateline aired an investigation which accused Parke-Davis of deliberately falsifying medical information about Neurontin so doctors would prescribe the drug off label to treat a multitude of conditions. State and Federal prosecutors have launched investigations into the allegedly illegal marketing of Neurontin. In its year-long investigation, Dateline interviewed a former Parke-Davis scientist who alleges company officials encouraged him to persuade physicians to prescribe Neurontin for a number of disorders, including attention deficit disorder and bipolar disease, even though there was minimal preliminary data indicating that Neurontin could help patients with those diseases.

In May 2003, The U.S. attorney's office in Boston said in court documents that the drug company Parke-Davis, now Pfizer, gave illegal kickbacks to doctors, including trips to Puerto Rico and tickets to the 1996 Summer Olympics in exchange for prescribing the anticonvulsant Neurontin. Below is a list of the off-label conditions that Neurontin was marketed to treat. These 11 uses were never submitted to the Food and Drug Administration (FDA) for approval, yet illegally promoted. Listed Below:

  • Bipolar Disorder
  • Pain Syndromes, Peripheral Neuropathy, and Diabetic Neuropathy
  • Treatment of Epilepsy alone (as monotherapy)
  • Reflex Sympathetic Dystrophy (RSD)
  • Attention Deficit Disorder (ADD)
  • Restless Leg Syndrome (RLS)
  • Trigeminal Neuralgia
  • Post-Hepatic Neuralgia (PHN)
  • Essential Tremor Periodic Limb Movement
  • Migraine
  • Drug and Alcohol Withdrawal Seizures

Legal Help For Victims Of Neurontin

If you or a loved one took Neurontin and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or Call us anytime at 1-800-YOURLAWYER (1-800-968-7529).


NeutrontinRSS Feed

High Court Rejects Pfizer's Request for RICO Off-Label Review

Sep 2, 2014
The United States Supreme Court has rejected an appeal from drug maker, Pfizer, letting stand a First Circuit ruling in which it was found that Pfizer improperly marketed Neurontin, its epilepsy drug, to Kaiser Foundation Health Plan. The High Court’s denial means that Pfizer must pay Kaiser $142 million in damages for violating the Racketeer Influenced and Corrupt Organizations (RICO) Act. Pfizer must also pay another $65.4 million in restitution for violating the California Unfair...

Illegal Neurontin Marketing to Cost Pfizer $142.1 Million

Mar 26, 2010 | Parker Waichman LLP
Pfizer Inc. has been ordered to pay  $142.1 million in damages for violating a federal antiracketeering law in its marketing of the epilepsy drug, Neurontin. Plaintiffs Kaiser Foundation Health Plan Inc. and Kaiser Foundation Hospitals had accused Pfizer of promoting Neurontin for uses not cleared by the Food & Drug Administration, including treatment for migraines and bipolar disorder.The judge who presided over the Kaiser lawsuit, U.S. District Judge Patti Saris, is overseeing...

Pfizer Influenced Neurontin Studies

Nov 12, 2009 | Parker Waichman LLP
It has been known that Neurontin is associated with a significant—80 percent, accoring to a prior LA Times report—increase in suicidal ideation and actions. Now, Reuters, is reporting that internal Pfizer Inc. documents point to the drug maker having “altered or omitted unfavorable study findings to expand its epilepsy drug, Neurontin's, market,” citing U.S. researchers looking into how drug manufacturers massage research data. Pfizer is considered, said Reuters, the...

Neurontin Suicide Trial to Start Next Week

Jul 24, 2009 | Parker Waichman LLP
The first Neurontin suicide lawsuit is set to go to trial.  According to a report on, about 1200 similar Neurontin lawsuits are pending.Neurontin was approved by the U.S. Food & Drug Administration (FDA) in 1983 to treat partial complex seizures.  The drug quickly became a blockbuster, and by 2004, sales reached $3 billion per year.  Neurontin was made by Parke-Davis, a division of Warner-Lambert, which was acquired by Pfizer in 2000.The first Neurontin lawsuit...

Illegal Marketing of Neurontin Detailed

Jan 8, 2009 | Parker Waichman LLP
An article detailing the marketing of Neurontin  recently published in the New England Journal of Medicine (NEJM) sheds new light on the tactics used by drug makers to increase sales of their products.  In the case of Neurontin, these methods were uncovered because they were being used to illegally promote off-label uses of the drug.  However, the authors of the NEJM article contend that the same questionable  tactics are regularly  used to promote approved of uses of...

More Neutrontin News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo